ADMA Biologics, Inc.
NASDAQ:ADMABiotechnology
+$0.04 today
- Market cap
- $3.01B
- Beta
- 0.73
- P/E (TTM)
- 12.1
- EPS (TTM)
- $0.70
Volume 3.17M
Average 7.07M
ADMA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
ADMA Biologics, Inc.NASDAQ: ADMA
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $37.82M rose 10.5% year over year, ahead of the -19.1% change in trailing-twelve-month net income. Sequentially, it fell 16.6% from the prior quarter.
Context
- Net income amounted to 28.8% of revenue in FY2025, down 17.6 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of $201.43M (+37.1%) for the fiscal year ending Dec 2026, a step up from the -25.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $37.82M-16.6% QoQ
- Last fiscal yearDec 2025
- $146.93M-25.7% YoY
- LTMJun 2026
- $168.96M-19.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +10.5% | +21.9% | +11.4 pp |
| 1 year | -25.7% | +37.1% | +62.8 pp |
| 3-year CAGR | — | +22.7% | — |
| 5-year CAGR | +22.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 146.93M USD
- Year-over-year change
- -25.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 146.93M | -25.7% |
| FY2024 | 2024-12-31 | 197.67M | +800.0% |
| FY2023 | 2023-12-31 | (28.24M) | +57.2% |
| FY2022 | 2022-12-31 | (65.9M) | +8.0% |
| FY2021 | 2021-12-31 | (71.65M) | — |
Net Income vs competitors
How ADMA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -19.1% is the 3rd highest of 4, against a peer median of +168.4%.
- Net income amounts to 33.0% of revenue for ADMA, versus a peer median of 84.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €798.42M EUR | +168.4% | +2.2% | 10.7% | |
| LTM Jun 2026 | $168.96M USD | -19.1% | — | 33.0% | |
| LTM Mar 2026 | $160.72M USD | +309.9% | -21.6% | 84.0% | |
| LTM Mar 2026 | $77.6M USD | -45.6% | -39.9% | 138.9% | |
| Peer median (excluding ADMA) | — | +168.4% | -21.6% | 84.0% | |
Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.65M) | (65.9M) | (28.24M) | 197.67M | 146.93M |
| Depreciation & Amortization | 5.5M | 7.11M | 8.33M | 8.05M | 8.1M |
| Deferred Income Tax | 220.76K | 0 | 0 | (84.28M) | 11.02M |
| Stock-Based Compensation | 3.49M | 5.22M | 6.19M | 13.62M | 20.03M |
| Change in Working Capital | (51.68M) | (18.29M) | (10.12M) | (18.54M) | (139.6M) |
| Accounts Receivables | (15.34M) | 13.07M | (11.92M) | (22.58M) | (108.43M) |
| Inventory | (43.19M) | (38.56M) | (9.63M) | 2.67M | (36.23M) |
| Accounts Payables | 1.36M | 799.98K | 3.84M | 4.15M | 2.33M |
| Other Working Capital | 5.49M | 6.4M | 7.58M | (2.78M) | 2.74M |
| Other Non-Cash Items | 1.75M | 12.35M | 32.64M | 2.16M | 3.92M |
| Operating Cash Flow | (112.37M) | (59.51M) | 8.8M | 118.67M | 50.4M |
| Capital Expenditures | (13.51M) | (13.91M) | (4.98M) | (8.58M) | (22.58M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 1M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (210K) | (349K) | (316K) |
| Investing Cash Flow | (13.51M) | (13.91M) | (4.98M) | (8.58M) | (21.89M) |
| Debt Repayment | (34K) | 51.71M | (23.6M) | (60M) | (3.18M) |
| Common Stock Issued | 121.14M | 64.65M | 0 | 7.49M | 2.98M |
| Common Stock Repurchased | 0 | 0 | (1.42M) | 0 | (31.94M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (62K) | (7.51M) | (13.97M) | (5.8M) | (11.89M) |
| Financing Cash Flow | 121.05M | 108.85M | (38.99M) | (58.3M) | (44.02M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.83M) | 35.43M | (35.17M) | 51.8M | (15.52M) |
| Free Cash Flow | (125.88M) | (73.42M) | 3.82M | 110.1M | 27.82M |
ADMA Biologics, Inc.
NASDAQ:ADMA
Intrinsic Alpha fair value
Locked
Current Price
$13.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.